Off-label use - Interpharma

Putting the focus on patients

Off-label use

A more efficient reimbursement process is needed to ensure that patients in Switzerland can benefit sooner from medical innovation.

Overview Off-label use Orphan drugs Pricing Rationing The authorisation and reimbursement process

In Switzerland, only medicines that have been examined by the therapeutic products agency Swissmedic for safety, efficacy and quality and authorised by Swissmedic may be used. However, doctors are free to select the therapy that they believe is most suitable for the patient’s needs, and in this context it is not uncommon for medicines to be prescribed that have been authorised but are administered for conditions for which they are not intended. This is nearly always the case when treating newborn babies, and more than half of children are treated with medicines used “off-label”, or in other words for purposes not listed in the Information for healthcare professionals. About one quarter of adults are treated with medicines used off-label.

There are many reasons why medicines are used off-label. When clinical research involving children is performed, for example, there are some particularly complex ethical aspects that need to be taken into account. For rare diseases it will never be possible to achieve full authorisation for individual indications because the number of patients involved is too small for clinical trials to be carried out.

Unequal treatment in reimbursement

Medicinal products used off-label can be reimbursed if certain strict criteria are met (Art. 71a-d HIO). The medicine must be used to treat a life-threatening disease, and this must be compatible with the objective of protecting health. In addition, use of the medicine must be expected to lead to major therapeutic progress, and there must be no other, comparable medicine available. The decision whether to reimburse the cost of using the medicine lies with the health insurance provider.

Against this background, access to and reimbursement of medicines used off-label are not always equal for everyone. Depending on the insurance provider, some patients may be treated unequally, as is also the case if decisions differ.

Weitere Informationen

About us

Interpharma, the association of Switzerland’s research-based pharmaceutical industry, was founded in Basel in 1933.

Interpharma informs the public about issues that are important to the research-based pharmaceutical industry in Switzerland, including the pharma market in Switzerland, healthcare and biomedical research.

Annual report

Information on our key figures and activities in the financial year 2023

read more

Board and Executive Management

Introducing Interpharma

read more

Vision and Mission

More about the tasks and overriding aims of Interpharma

read more


Contact us

read more


Latest information and media contacts for media representatives

read more